India's listed hospital sector contains a seeming contradiction.

The speciality chains that do one thing, and do it very well — the eye-care chains, the children's hospitals, the cancer centres — make more profit on every rupee of revenue than the big do-everything hospital networks.

But when investors decide what these companies are worth, they consistently pay more for the generalists.

The specialist runs the tighter ship and gets marked down for it. The generalist runs the looser ship and commands a premium.

It looks like the market has its wires crossed. But follow the numbers and the picture becomes clearer. Investors aren’t pricing this year’s profits so much as betting on the hospital beds companies will add over the next decade.

On that measure, the specialist's excellence turns out to be its handicap.

A quick word on method.

The figures below cover 27 listed hospital chains, using each company's most recent twelve months of results as of 13 August 2026.

For chains that had filed April-June 2026 (Q1 FY27) results by that date, the twelve months run from July 2025 to June 2026; for the rest, they equal FY26.

Where the piece refers to valuation history, it uses month-by-month records going back to May 2019, or to whenever a company listed.

Who’s More Profitable?

Three listed hospital companies focus on a single field of medicine and have enough of a financial record to measure. Dr Agarwal's Health Care in eye care, Rainbow Children's Medicare in paediatrics, and HCG in cancer treatment.

The measure that matters here is the operating (EBITDA) margin. Out of every Rs 100 a hospital bills, how much is left as profit after paying doctors, nurses, medicines and running costs, before interest, tax and accounting charges. On this yardstick, the specialists keep about Rs 29.5 of every Rs 100. Rainbow, the children's hospital chain, keeps Rs 33.5.

The six biggest do-everything networks, Apollo, Max Healthcare, Fortis, Aster DM, Medanta and KIMS, keep about Rs 21.8. The wider set of general hospital chains manages about Rs 21.

That is a gap of nearly nine rupees in every hundred. It is not a rounding error.

The focused operators genuinely convert revenue into profit more efficiently than the sprawling ones.

What Are Investors Looking For?

Now look at what the market is willing to pay for those profits.

The standard way to compare hospital valuations is to ask: how much does the market pay for every rupee of a company's annual operating profit? (The price tag here includes the company's debt, since a buyer would inherit it.)

Markets call this ratio EV/EBITDA, enterprise value against operating profit. A higher number means investors expect those profits to grow, and to grow a lot.

The six big generalists are priced, on average, at Rs 39 for every Rs 1 of annual operating profit, an EV/EBITDA of 39.

Aster is at nearly 46 times, KIMS at 43, Max at almost 42. The three specialists cluster at an EV/EBITDA of 24 to 25. Investors are paying roughly 60% more per rupee of profit for the businesses that earn less profit per rupee of revenue.

Is there any link at all between how profitable a hospital chain is and how richly it is valued? Across the 20 chains where both can be measured, the answer is no.

The statistical relationship is zero.

Plot the sector on a chart, profitability along one axis, valuation along the other, and you get a shapeless cloud. Whatever investors are paying for, it is not efficiency.

What Are They Paying For?

The expensive names all have one thing in common: they are building.

India's hospital chains are on course to add roughly 34,000 new beds by FY29, at a cost of over Rs 40,000 crore, according to ICRA.

Max targets 10,000 beds by FY30, roughly double its current base, with Rs 6,000 crore of planned spending, and holds land parcels for close to 4,000 further beds beyond FY30. The merged Aster DM Quality Care plans about 4,080 beds in two years for around Rs 4,000 crore, per an interview with Aster’s deputy managing director Alisha Moopen. Yatharth wants roughly 5,000 beds within three years.

The broker Antique argued in June 2026 that oversupply fears were misplaced: "We believe sector growth will continue to be driven from bed expansion". Investors are buying the hospital network of 2032, at 2026 prices.

Correlation is not proof, and the objection is fair: the richly valued chains might simply happen to be builders.

Two tests separate the stories.

Within single companies, the premium moved when the pipeline moved: Aster and KIMS re-rated as their bed plans firmed up, while their margins changed little over the same stretch. And the sector supplies a control.

The clearest proof comes from the exception.

Narayana Hrudayalaya, the chain built by the heart surgeon Devi Shetty, is a large and well-run general hospital network. But its management said plainly on its July 2026 earnings call that no meaningful beds are coming in the next two to three years, choosing instead to treat more patients within its existing hospitals; the roughly 1,535 beds it has planned across Bengaluru, Kolkata and Raipur land later.

Narayana is valued at an EV/EBITDA of about 23. That is below all three specialists, and roughly half the level of Aster or KIMS. Same format, same size class, no near-term expansion, no premium. The market could hardly be clearer about what it is buying.

The Ceiling Problem

So why does the specialist not get the same credit for growth? Because everyone can see the ceiling above its head.

Eye care is a sliver of what Indians spend on healthcare delivery each year, and Dr. Agarwal's already commands about a quarter of India's organised eye-care chain market, according to CRISIL MI&A estimates cited in its IPO prospectus.

When a company already owns a quarter of its entire addressable market, the remaining runway is visible to everyone. A children's hospital chain faces similar arithmetic.

However dominant the operator and however healthy the margin, a company confined to one field of medicine has a hard limit on how big it can ever become. A general hospital network faces no such limit, and can lean into whichever specialities are growing fastest.

A share price is, at bottom, a bet on all the profits a company will ever make. A 33% EBITDA margin on a market that tops out is often worth less than a 22% one on a market that does not.

The Profit Edge May Not Last

There is a second reason investors decline to pay up for specialist margins: the margins may not really belong to the format.

Consider KIMS, the Hyderabad-based general hospital group.

Its established Telangana cluster earned Rs 682 crore of operating profit on Rs 2,242 crore of revenue in FY26, keeping about Rs 30.4 of every Rs 100 billed, as much as the eye and children's chains; on its July 2026 earnings call, management guided that Telangana should sustain 30 to 35% margins as newer units scale.

The group's overall FY26 margin of about Rs 21 looks lower only because its newer hospitals in Karnataka, Maharashtra, and Kerala are still filling up. In other words, a mature general hospital earns specialist-grade margins. Much of the gap between the two formats is simply age, not some structural advantage of focus.

Cancer care makes the same point from the other side. HCG, the specialist in oncology, runs an EBITDA margin of only about 17.7%, less than the average generalist and about the same as a mid-sized general hospital like Artemis.

Focus produces fat margins in eyes and children but not in tumours, where the big networks run their own cancer wings and compete for the same surgeons and the same radiation machines.

Nor do the specialists grow cheaply.

Dr. Agarwal's added 57 facilities in FY26 to take its network to 288, and CEO Dr. Adil Agarwal told the FY26 earnings call that the coming year's 60-facility plan means a "total CapEx spend being around INR380 to INR400 crores". Rainbow's management, on its own July 2026 call, laid out a five-year plan: "we plan to add 2,500 beds to expand our network capacity to 5,000 beds", at an estimated Rs 2,200 crore. Growth in this industry is bought with concrete and imported equipment, whatever the signboard says.

The generalists are also moving onto the specialists' turf.

On Apollo's May 2026 earnings call, management described its deeply integrated mother-and-child format as one it will keep growing in key markets, citing the "huge difference in terms of the value that you get" in revenues and margins; the group has also combined Apollo Cradle and Fertility with Cloudnine into one of India's largest maternity and fertility platforms.

Rainbow, meanwhile, spends time on its own investor calls explaining why it is better than smaller boutique paediatric rivals. The specialist is being squeezed from below by other specialists and from above by giant brands with vast referral networks.

Where The Puzzle Was Never Real

Two parts of the original irony do not survive contact with the data at all.

First, on the most commonly quoted measure of all, the price-to-earnings or P/E ratio, the share price compared to profit after tax, the specialists are not cheap. They are dearer than the generalists.

That is because their impressive operating margins shrink dramatically by the time interest, tax and expansion costs are paid: the specialists keep only about Rs 6.7 of every Rs 100 as final profit, a net margin below 7%, against Rs 11 for the generalists.

Returns on capital blur the edge further. Hospital growth is paid for in buildings and machines that depreciate for decades, and a measure that stops before depreciation, interest and tax will flatter whoever has built most recently.

The net profit figures above show what remains once those costs are counted: the specialists' advantage inverts. EBITDA is used here because it is the sector's common currency and the yardstick kindest to the specialists. Even on their most flattering measure, the market declines to pay up.

HCG's net margin is so thin, under 1%, that its P/E looks absurd. The fairer lens, and the one used throughout this piece, is EV/EBITDA.

Second, the cheapest hospitals in India are not the specialists. They are the small regional generalists.

Kovai Medical in Coimbatore is valued at an EV/EBITDA of about 14, Indraprastha Medical in Delhi at 11, Shalby at 13. Kovai earns specialist-grade EBITDA margins, nearly Rs 30 in every Rs 100, and yet in seven years of monthly records its EV/EBITDA has never crossed roughly 18. If fat margins attracted a premium, Kovai should be expensive. It is the cheapest of all.

It Was A Size Premium All Along

Line the whole sector up by size, and the pattern snaps into place.

Using each company's typical valuation over the same three and a half years, February 2023 to July 2026: Max, the sector's darling, commands a median EV/EBITDA of about 48. The big generalists as a group are at about 33. The specialists come next at about 25. The small regional generalists trail at about 14.

Forty-eight, then 33, then 25, then 14, in perfect order of company size and expansion plans, and in no order at all of profitability. The specialists are not being punished for focus. They are mid-sized companies being priced like mid-sized companies, wedged between giants with published bed pipelines and regional operators with neither scale nor a growth story investors believe.

Can size and expected expansion be separated statistically? Not cleanly, in a listed set this small. The chains with the largest published bed pipelines are also, Narayana apart, the largest companies, so a regression of valuation on planned beds would mostly re-measure size.

What the data will support is the ranking itself: sequence the sector by enterprise value or by announced expansion and the valuation ladder reads in order; sequence it by EBITDA margin and the order dissolves.

The pairing of Rainbow and Max shows how stubborn this is. In every month since early 2023 for which both can be measured, Max has traded at a higher EV/EBITDA than Rainbow, typically by about 88%, and the premium has never inverted. It has eased only at the margin, and such easing as there is came from Max cooling off its April 2024 fever, not from investors warming to Rainbow, which has traded in the same band its entire listed life.

One caution about timing. Part of the generalists' premium is new. Aster spent 2019 to 2022 at a single-digit EV/EBITDA; today's 43 is the highest in its own seven-year record, and KIMS is close to its peak too. The bed-building story has been repriced sharply upward in the last two years. Whether those beds actually fill will decide whether today's ladder is a structure or a phase.

The Resolution

So the irony dissolves. Investors pay an EV/EBITDA of 33 to 48 for a claim on the whole of Indian healthcare delivery, backed by a published construction pipeline. They pay 24 for a superb margin earned inside a bounded field, where the advantage is partly an accident of age and the growth still demands heavy spending. The profitability is now. The price is about later. And for a single field of medicine, later is smaller.

The specialist's discount, read properly, is not the market failing to recognise excellence. It is the market refusing to confuse a well-run business with a large one.

Valuation multiples, margins and correlations are the author's computations from published financial statements of 27 listed hospital chains, as of 13 August 2026; historical multiples are computed on last filed period-end financials, month by month. Figures are historical and descriptive; nothing here is investment advice.